Literature DB >> 32238120

Drug-resistant tuberculosis: an experience from Qatar.

Maisa Ali1, Faraj Howady1, Waqar Munir1, Hanfa Karim1, Zubaida Al-Suwaidi2, Muna Al-Maslamani1, Abdullatif Alkhal1, Nada Elmaki1, Hisham Ziglam1.   

Abstract

This study was conducted to evaluate the characteristics, treatment outcome and risk factors associated with 223 drug-resistant tuberculosis (DR-TB) cases in the State of Qatar. A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010 - March 2015. Demographic, clinical data, drug-resistance pattern of isolated mycobacteria and treatment outcome was assessed for the patient who completed their treatment in Qatar. Of 3301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to at least one drug. The overall prevalence of multi-d rug resistant TB (MDR-TB) was 1.2% (n = 38) of patients. A former resident of Indian sub contents was the most common demographic characteristic observed (64.1%). The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment. Cure and relapse rates were 97.6%, and 2.4%, respectively. Drug-resistant TB in Qatar is influenced by migration where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug-susceptibility testing should be the standard of care.

Entities:  

Keywords:  Extra-Pulmonary TB; MDR-TB; Pulmonary TB; Rifampicin; XDR-TB

Mesh:

Substances:

Year:  2020        PMID: 32238120      PMCID: PMC7170354          DOI: 10.1080/19932820.2020.1744351

Source DB:  PubMed          Journal:  Libyan J Med        ISSN: 1819-6357            Impact factor:   1.657


  10 in total

1.  Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study.

Authors:  H S Subhash; I Ashwin; M V Jesudason; O C Abharam; G John; A M Cherian; K Thomas
Journal:  Indian J Chest Dis Allied Sci       Date:  2003 Apr-Jun

Review 2.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

3.  Demographic and microbial characteristics and drug resistance of childhood tuberculosis in Istanbul: analysis of 1,541 cases.

Authors:  Erkan Cakir; Ela Erdem; Nagihan Ozlu; Engin Seber; Serap Gencer; Zeki Kilicaslan
Journal:  J Infect Dev Ctries       Date:  2014-03-13       Impact factor: 0.968

Review 4.  Drug resistance in mycobacteria.

Authors:  D A Mitchison
Journal:  Br Med Bull       Date:  1984-01       Impact factor: 4.291

5.  Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.

Authors:  Sahal Al-Hajoj; Bright Varghese; Mohammed M Shoukri; Ruba Al-Omari; Mais Al-Herbwai; Fahad Alrabiah; Abdulrahman A Alrajhi; Naila Abuljadayel; Sahar Al-Thawadi; Alimuddin Zumla; Matteo Zignol; Mario C Raviglione; Ziad Memish
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

6.  Nationwide survey on the prevalence of anti-tuberculosis drug resistance in the Republic of Yemen, 2004.

Authors:  A Al-Akhali; A Ohkado; A Fujiki; S Mitarai; N Yamada; T Masui; K Otomo; H Yamada; A Seita; T Mori; A N Al-Absi
Journal:  Int J Tuberc Lung Dis       Date:  2007-12       Impact factor: 2.373

Review 7.  Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  Abigail Wright; Matteo Zignol; Armand Van Deun; Dennis Falzon; Sabine Ruesch Gerdes; Knut Feldman; Sven Hoffner; Francis Drobniewski; Lucia Barrera; Dick van Soolingen; Fadila Boulabhal; C N Paramasivan; Kai Man Kam; Satoshi Mitarai; Paul Nunn; Mario Raviglione
Journal:  Lancet       Date:  2009-04-15       Impact factor: 79.321

8.  Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes.

Authors:  Z Mor; D Goldblatt; H Kaidar-Shwartz; N Cedar; E Rorman; D Chemtob
Journal:  Int J Tuberc Lung Dis       Date:  2014-10       Impact factor: 2.373

9.  A study of Mycobacterium tuberculosis genotypic diversity & drug resistance mutations in Varanasi, north India.

Authors:  Anamika Gupta; Savita Kulkarni; Nalin Rastogi; Shampa Anupurba
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

Review 10.  First-Line Anti-Tubercular Drug Resistance of Mycobacterium tuberculosis in IRAN: A Systematic Review.

Authors:  Babak Pourakbari; Setareh Mamishi; Mona Mohammadzadeh; Shima Mahmoudi
Journal:  Front Microbiol       Date:  2016-07-28       Impact factor: 5.640

  10 in total
  2 in total

1.  HIV and AIDS-defining opportunistic illnesses in the state of Qatar: A cohort population-based retrospective study covering 17 years (2000-2016).

Authors:  Maisa Ali; Almurtada Razok; Mahmoud Gassim; Nada Elmaki; Wael Goravey; Abdulatif Alkhal; Muna Almaslamani; Hussam Alsoub
Journal:  Ann Med Surg (Lond)       Date:  2022-05-20

Review 2.  Emerging Status of Multidrug-Resistant Bacteria and Fungi in the Arabian Peninsula.

Authors:  J Francis Borgio; Alia Saeed Rasdan; Bayan Sonbol; Galyah Alhamid; Noor B Almandil; Sayed AbdulAzeez
Journal:  Biology (Basel)       Date:  2021-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.